This residue is altered to proline in a cancer-associated mutation that weakens DEPTOR binding to mTOR (Grabiner et al., 2014; Sato et al., 2010) and cannot be compensated by DEPTOR overexpression, underlining the functional relevance of this interaction (Figure 3b; Xu et al., 2016). This evidence concerns the gene DEPTOR and cancer.